CMG Pharmaceutical Co Ltd

CMG Pharmaceutical Co Ltd has a market price of 1,370 KRW per share, with a market capitalization of 202.54 billion KRW. The company's price-to-book ratio is 1.0, and its price-to-tangible-book ratio is also 1.0, indicating that the market value is in line with the book value of tangible assets. The enterprise value to EBITDA ratio is negative at -30.99, reflecting the company's current operating losses. The enterprise value to revenue ratio is 2.61, suggesting that the company is valued at 2.61 times its annual revenue.

The company's profitability is currently negative, with a return on equity of -5% and a return on assets of -3.29%. These figures indicate that the company is not generating returns for its shareholders or effectively utilizing its assets. The operating income is -8.86 billion KRW, and the net income is -10.08 billion KRW, showing a significant decline in profitability. The gross profit margin is 57.9%, which is relatively high but insufficient to offset the company's operating and net losses.

CMG Pharmaceutical Co Ltd's revenue is concentrated in a single geographic region, South Korea, with no disclosed international operations. The company's total revenue for the period is 105.23 billion KRW. There are no disclosed segments, and the company does not provide a breakdown of revenue by product or geographic region.

The company's growth trajectory is currently negative, with a net loss of 10.08 billion KRW and a free cash flow of -40.01 billion KRW. The operating cash flow is also negative at -11.02 billion KRW, indicating that the company is not generating sufficient cash from its operations to sustain its activities. The capital expenditure is -33.01 billion KRW, suggesting that the company is investing in its operations but is not generating positive cash flow from these investments.

The company faces medium liquidity risk, as indicated by a current ratio of 0.92, which is below 1, suggesting that the company may struggle to meet its short-term obligations. The debt-to-equity ratio is 0.36, indicating a relatively low level of debt compared to equity. However, the company's net cash position is negative after subtracting total debt, which could pose a risk to its liquidity. The dilution risk is currently low, with no significant dilution expected in the near term.

There are no recent events or filings disclosed that would significantly impact the company's operations or financial position. The company's financial performance and risk profile suggest that it is currently facing challenges in maintaining profitability and liquidity.